Zealand Pharma AS (ZEAL) Stock Overview
USA - NASDAQ:ZEAL - US98920Y3045 - ADR
ZEAL Key Statistics, Chart & Performance
The current stock price of ZEAL is 17.59 USD. In the past month the price decreased by -5.35%. In the past year, price decreased by -48.7%.
ZEAL Latest News, Press Relases and Analysis
ZEAL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.75 | 406.84B | ||
| AMGN | AMGEN INC | 13.41 | 157.42B | ||
| GILD | GILEAD SCIENCES INC | 15.27 | 146.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.05 | 104.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.95B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.22 | 59.11B | ||
| ARGX | ARGENX SE - ADR | 86.25 | 48.93B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.28 | 35.92B | ||
| INSM | INSMED INC | N/A | 34.65B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.59B | ||
| NTRA | NATERA INC | N/A | 23.90B | ||
| BIIB | BIOGEN INC | 9.04 | 21.21B |
Related stock screener links
About ZEAL
Company Profile
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Company Info
Zealand Pharma AS
Sydmarken 11
Soeborg 2860 DK
CEO: Emmanuel Dulac
Employees: 237
Phone: 4588773600.0
Zealand Pharma AS / ZEAL FAQ
What is the stock price of Zealand Pharma AS today?
The current stock price of ZEAL is 17.59 USD. The price increased by 1.21% in the last trading session.
What is the ticker symbol for Zealand Pharma AS stock?
The exchange symbol of Zealand Pharma AS is ZEAL and it is listed on the Nasdaq exchange.
On which exchange is ZEAL stock listed?
ZEAL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Zealand Pharma AS stock?
14 analysts have analysed ZEAL and the average price target is 28.31 USD. This implies a price increase of 60.93% is expected in the next year compared to the current price of 17.59. Check the Zealand Pharma AS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Zealand Pharma AS worth?
Zealand Pharma AS (ZEAL) has a market capitalization of 811.25M USD. This makes ZEAL a Small Cap stock.
How many employees does Zealand Pharma AS have?
Zealand Pharma AS (ZEAL) currently has 237 employees.
What are the support and resistance levels for Zealand Pharma AS (ZEAL) stock?
Zealand Pharma AS (ZEAL) has a support level at 16.62 and a resistance level at 19.15. Check the full technical report for a detailed analysis of ZEAL support and resistance levels.
Is Zealand Pharma AS (ZEAL) expected to grow?
The Revenue of Zealand Pharma AS (ZEAL) is expected to grow by 13.79% in the next year. Check the estimates tab for more information on the ZEAL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Zealand Pharma AS (ZEAL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZEAL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZEAL, evaluating the profitability, health, valuation and growth aspects
- Zealand Pharma AS (ZEAL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Zealand Pharma AS (ZEAL) Sales and EPS estimates to see what analysts future expectations are.
- Zealand Pharma AS (ZEAL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Zealand Pharma AS (ZEAL) Insider and Institutional Ownership to learn about the owners and their transactions.
- Zealand Pharma AS (ZEAL) Stock Chart to make your own analysis
- Zealand Pharma AS (ZEAL) Latest news and press-releases to stay up to date.
Does Zealand Pharma AS (ZEAL) stock pay dividends?
ZEAL does not pay a dividend.
When does Zealand Pharma AS (ZEAL) report earnings?
Zealand Pharma AS (ZEAL) will report earnings on 2022-11-09.
What is the Price/Earnings (PE) ratio of Zealand Pharma AS (ZEAL)?
Zealand Pharma AS (ZEAL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.45).
ZEAL Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ZEAL. When comparing the yearly performance of all stocks, ZEAL is one of the better performing stocks in the market, outperforming 70.51% of all stocks.
ZEAL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZEAL. While ZEAL seems to be doing ok healthwise, there are quite some concerns on its profitability.
ZEAL Financial Highlights
Over the last trailing twelve months ZEAL reported a non-GAAP Earnings per Share(EPS) of -3.45. The EPS increased by 3.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -583.94% | ||
| ROA | -94.74% | ||
| ROE | N/A | ||
| Debt/Equity | 0.93 |
ZEAL Forecast & Estimates
14 analysts have analysed ZEAL and the average price target is 28.31 USD. This implies a price increase of 60.93% is expected in the next year compared to the current price of 17.59.
For the next year, analysts expect an EPS growth of -5.24% and a revenue growth 13.79% for ZEAL